BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8162054)

  • 1. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
    St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
    Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
    Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
    Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
    Grompe M; al-Dhalimy M
    Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
    Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
    J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
    Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
    Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
    Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
    Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
    Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
    N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
    Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
    Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
    Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.
    Rootwelt H; Kristensen T; Berger R; Høie K; Kvittingen EA
    Hum Genet; 1994 Sep; 94(3):235-9. PubMed ID: 8076937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1.
    Rootwelt H; Berger R; Gray G; Kelly DA; Coşkun T; Kvittingen EA
    Am J Hum Genet; 1994 Oct; 55(4):653-8. PubMed ID: 7942842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-induced correction of the genetic defect in tyrosinemia type I.
    Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
    J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
    Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
    Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I.
    Timmers C; Grompe M
    Hum Mutat; 1996; 7(4):367-9. PubMed ID: 8723690
    [No Abstract]   [Full Text] [Related]  

  • 15. Two novel mutations involved in hereditary tyrosinemia type I.
    St-Louis M; Poudrier J; Phaneuf D; Leclerc B; Laframboise R; Tanguay RM
    Hum Mol Genet; 1995 Feb; 4(2):319-20. PubMed ID: 7757089
    [No Abstract]   [Full Text] [Related]  

  • 16. Fumarylacetoacetase mutations in tyrosinaemia type I.
    Rootwelt H; Høie K; Berger R; Kvittingen EA
    Hum Mutat; 1996; 7(3):239-43. PubMed ID: 8829657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
    Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I.
    Awata H; Endo F; Tanoue A; Kitano A; Nakano Y; Matsuda I
    Biochim Biophys Acta; 1994 May; 1226(2):168-72. PubMed ID: 8204664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
    Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
    Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency.
    Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R
    Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.